EVGN
Price
$0.40Alerts
Change
+$0.03 (+8.11%)
Updated
Nov 11 closing price
Capitalization
4.28M
8 days until earnings call
Intraday BUY SELL Signals
INSM
Price
$120.75Alerts
Change
+$1.26 (+1.05%)
Updated
Nov 11 closing price
Capitalization
24.98B
106 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EVGN vs INSM

EVGN vs INSM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EVGN vs. INSM commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVGN is a Hold and INSM is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for EVGN with price predictions
Nov 10, 2026

EVGN in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026

EVGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 45 cases where EVGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EVGN's RSI Indicator exited the oversold zone, 34 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 74 cases where EVGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.

The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on EVGN as a result. In 67 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +37.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVGN advanced for three days, in 141 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EVGN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for EVGN entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-1.302) is normal, around the industry mean (3.498). P/E Ratio (-0.366) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.012) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. EVGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for INSM with price predictions
Nov 10, 2026

INSM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for INSM turned positive on October 27, 2026. Looking at past instances where INSM's MACD turned positive, the stock continued to rise in 42 of 52 cases over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on INSM as a result. In 66 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.

INSM moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 201 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

INSM broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INSM entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. INSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.982) is normal, around the industry mean (3.498). P/E Ratio (-27.768) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
EVGN vs INSM: Fundamental Ratings
EVGN
INSM
OUTLOOK RATING
1..100
4535
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10054
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9157
P/E GROWTH RATING
1..100
954
SEASONALITY SCORE
1..100
4550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVGN's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for INSM (79). This means that EVGN’s stock grew somewhat faster than INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for EVGN (100). This means that INSM’s stock grew somewhat faster than EVGN’s over the last 12 months.

INSM's SMR Rating (98) in the Biotechnology industry is in the same range as EVGN (100). This means that INSM’s stock grew similarly to EVGN’s over the last 12 months.

INSM's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for EVGN (91). This means that INSM’s stock grew somewhat faster than EVGN’s over the last 12 months.

EVGN's P/E Growth Rating (9) in the Biotechnology industry is somewhat better than the same rating for INSM (54). This means that EVGN’s stock grew somewhat faster than INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVGNINSM
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
71%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
69%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 9 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (EVGN: $0.37 vs. INSM: $119.49)
Brand notoriety: EVGN and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EVGN: 746% vs. INSM: 100%
Market capitalization -- EVGN: $4.28M vs. INSM: $24.98B
EVGN [@Biotechnology] is valued at $4.28M. INSM’s [@Biotechnology] market capitalization is $24.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVGN’s FA Score shows that 2 FA rating(s) are green while INSM’s FA Score has 0 green FA rating(s).

  • EVGN’s FA Score: 2 green, 3 red.
  • INSM’s FA Score: 0 green, 5 red.
According to our system of comparison, EVGN is a better buy in the long-term than INSM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVGN’s TA Score shows that 5 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).

  • EVGN’s TA Score: 5 bullish, 3 bearish.
  • INSM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, EVGN is a better buy in the short-term than INSM.

Price Growth

EVGN (@Biotechnology) experienced а +5.89% price change this week, while INSM (@Biotechnology) price change was +14.41% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

EVGN is expected to report earnings on Nov 19, 2026.

INSM is expected to report earnings on Feb 25, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.